{
    "clinical_study": {
        "@rank": "117536", 
        "arm_group": [
            {
                "arm_group_label": "Apparently healthy subjects"
            }, 
            {
                "arm_group_label": "Non-malignant conditions subjects"
            }, 
            {
                "arm_group_label": "Malignant conditions subjects"
            }
        ], 
        "biospec_descr": {
            "textblock": "Serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Aim of this study is to provide specimens for establishing reference values of HE4 in an\n      apparently healthy Chinese population using the Roche Elecsys HE4 assay tested on variety of\n      Elecsys and cobas brand immunoassay analyzers. This reference range will be compared to\n      population of subjects who have signs and symptoms of various benign and malignant diseases,\n      including ovarian cancer. This reference range will also be compared to the levels of HE4 in\n      individual subjects who have been diagnosed with ovarian cancer and are being followed\n      longitudinally for recurrence or progression of their disease."
        }, 
        "brief_title": "Elecsys HE4 Chinese Reference Value Study", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (all cohorts):\n\n          -  appropriate clinical data\n\n          -  normal appearance of sample\n\n          -  minimum 0.5 ml volume available\n\n        Exclusion Criteria (all cohorts):\n\n          -  < 18 years of age\n\n          -  insufficient volume\n\n          -  insufficient clinical information\n\n          -  > 3 freeze/thaw cycles of samples\n\n          -  Stored or shipped at  > 0\u00b0C\n\n          -  Icteric, lipemic, hemolytic, substantial particulates"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Except for samples from apparently healthy subjects, specimens for the entire clinical\n        section are supposed to be available in banks / archives. Thus, for the most part, no\n        prospective collection of serum should be necessary. Pseudonymized residual samples will\n        be used. All elements of the clinical part require samples from well characterized cohorts\n        are showed below.\n\n          1. Apparently Healthy: 300\n\n          2. Non-malignant Conditions: 650\n\n          3. Malignant Conditions: 800"
            }
        }, 
        "enrollment": {
            "#text": "2351", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738269", 
            "org_study_id": "CIM RD001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Ovarian cancer, HE4, normal range", 
        "lastchanged_date": "July 30, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "China PLA General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China"
                    }, 
                    "name": "The First Affiliated Hospital of Fujian Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "Sun Yat-Sen University Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China"
                    }, 
                    "name": "Shandong University Qilu Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Fudan University Shanghai Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }, 
                    "name": "Tianjin Cancer Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Urumchi", 
                        "country": "China"
                    }, 
                    "name": "Xinjiang Medical University Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China"
                    }, 
                    "name": "Tongji Hospital Tongji Medical Colege of HUST"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xiamen", 
                        "country": "China"
                    }, 
                    "name": "Zhongshan Hospital Xiamen University"
                }
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "3", 
        "official_title": "A Multi-center Reference Value Study of Elecsys HE4 in Chinese Population", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Establish reference in Chinese population", 
            "safety_issue": "No", 
            "time_frame": "October 2012 - March 2013"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738269"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "Yaping Tian", 
            "investigator_title": "Director of Biochemistry Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}